Sbir concept award - therapeutics - sulfonyl-urea and sulfonamide PP2A activators as mycn amplified neuroblastoma (NBL) therapeutics
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91024C00009
- Awardee
-
Atux Iskay Group LLC UEI C7JPQ5F3UUH7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $355,000
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2024 Pre-Solicitation · 75N91023R00034 · Posted Feb 27, 2023
- Contract value 100% obligated
- $355,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 27 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Plainsboro Township, NJ 08536, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $355,000 |
About this award
This is a $355,000.00 Small Business Innovation Research (SBIR) Concept Award contract awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Atux Iskay Group LLC, a for-profit limited liability company. The contract supports the development of sulfonyl-urea and sulfonamide protein phosphatase 2A (PP2A) activators as potential therapeutics for MYCN amplified neuroblastoma, a rare pediatric cancer. The work is designated as a SBIR Program Phase I action, focused on demonstrating technical feasibility and proof-of-concept. This is a firm fixed price contract and a total small business set-aside.
Quick answers
Who was awarded contract 75N91024C00009?
75N91024C00009 was awarded to Atux Iskay Group LLC by National Cancer Institute (National Institutes of Health) on February 15, 2024.
How much is contract 75N91024C00009 worth?
The government has obligated $355,000 on 75N91024C00009.
Was contract 75N91024C00009 competed?
The extent of competition for 75N91024C00009 was full and open competition after exclusion of sources. The government received 27 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award